Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Skye Bioscience Inc.

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Skye Bioscience to Announce Third Quarter 2024 Results
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.